

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)
Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | DOCUMENT NUMBER | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|------------------|-----------------------|-------------------------------|--------------------------------|--|--|
| | | Number-Kind Code ² | | | |
| CA | A | 5,587,458 | 12-24-1996 | C. Richter King et al. | |
| CA | B | 5,747,498 | 05-05-1998 | Rodney Caughren Schnur | |
| CA | C | 5,792,783 | 08-11-1998 | Peng Cho Tang et al. | |
| CA | D | 5,834,504 | 11-10-1998 | Peng Cho Tang et al. | |
| CA | E | 5,861,510 | 01-19-1999 | Anthony Piscopio et al. | |
| CA | F | 5,863,949 | 01-26-1999 | Ralph P. Robinson et al. | |
| CA | G | 5,877,305 | 03-02-1999 | James S. Huston et al. | |
| CA | H | 5,883,113 | 03-16-1999 | Peng Cho Tang et al. | |
| CA | I | 5,886,020 | 03-23-1999 | Peng Cho Tang et al. | |
| CA | J | 6,071,935 | 06-06-2000 | Joseph P. Lyssikatos | |
| CA | K | 6,502,129 | 12-31-2002 | Daniel B. Stewart et al. | |
| CA | L | 6,492,383 | 12-2002 | Munchhof et al. | |
| CA | M | 6,225,318 | 05-01-2001 | | |
| CA | N | 6,492,383 | 12-10-2002 | | |

FOREIGN PATENT DOCUMENTS

| EXAMINER INITIAL | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
|------------------|-----------------------|--|--------------------------------|--|--|----------------|
| | | Country Code ³ Number ⁴ Kind Code ⁵ (if known) | | | | |
| CA | AL | WO 90/05719 | 05-31-1990 | British Bio-Technology Limited | | |

EXAMINER:

AULAKH

DATE CONSIDERED:

9-14-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant may place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

| | | | | | | |
|------------------------------|--|--|--|--|--------------------------|------------------------|
| Substitute for form 1449/PTO | | | | | Complete if Known | |
| | | | | | Application Number | to be assigned |
| | | | | | Filing Date | March 9, 2004 |
| | | | | | First Named Inventor | Michael Collins et al. |
| | | | | | Art Unit | 1625 |
| | | | | | Examiner Name | Charanjit Aulakh |
| | | | | | Attorney Docket Number | PC19103B |

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use as many sheets as necessary)

| | | | | | | |
|----|----|-------------|------------|---------------------------|--|--|
| CA | AM | EP-0606,046 | 12-21-1993 | Novartis AG | | |
| CA | AN | WO 95/19970 | 07-27-1995 | Warner-Lambert Company | | |
| CA | AO | WO 95/21613 | 08-17-1995 | Sugen, Inc. & Yssum | | |
| CA | AP | WO 95/23141 | 08-31-1995 | Pfizer Inc. | | |
| CA | AQ | WO 96/14843 | 05-23-1996 | Cor Therapeutics, Inc. | | |
| CA | AR | WO 96/27583 | 09-12-1996 | Pfizer Inc. | | |
| CA | AS | WO 96/30347 | 10-03-1996 | Pfizer Inc. | | |
| CA | AT | WO 96/33172 | 10-24-1996 | Pfizer Inc. | | |
| CA | AU | WO 96/40142 | 12-19-1996 | Pfizer Inc. | | |
| CA | AV | WO 97/13771 | 04-17-1997 | Glaxo Group Limited | | |
| CA | AW | WO 97/13760 | 04-17-1997 | Glaxo Group Limited | | |
| CA | AX | WO 97/22596 | 06-26-1997 | Zeneca Limited | | |
| CA | AY | WO 97/32856 | 09-12-1997 | Zeneca Limited | | |
| CA | AZ | WO 97/34876 | 09-25-1997 | Zeneca Limited | | |
| CA | BA | WO 97/49688 | 12-31-1997 | Pfizer, Inc. | | |
| CA | BB | WO 98/01113 | 01-15-1998 | Seiken Chemical Co., LTD. | | |
| CA | BC | WO 98/02434 | 01-22-1998 | Glaxo Group Limited | | |
| CA | BD | WO 98/02438 | 01-22-1998 | Glaxo Group Limited | | |
| CA | BE | WO 98/02437 | 01-22-1998 | Glaxo Group Limited | | |
| CA | BF | WO 98/03516 | 01-29-1998 | Pfizer Inc. | | |

EXAMINER:

DATE CONSIDERED:

AULAKH

9-14-04

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. 'Applicant's unique citation designation number (optional). 25See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16If possible, 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

| | | | |
|------------------------------|--|--------------------------|------------------------|
| Substitute for form 1449/PTO | | Complete if Known | |
| | | Application Number | to be assigned |
| | | Filing Date | March 9, 2004 |
| | | First Named Inventor | Michael Collins et al. |
| | | Art Unit | 1625 |
| | | Examiner Name | Charanjit Aulakh |
| | | Attorney Docket Number | PC19103B |

| | | | | | | |
|----|----|-------------|------------|------------------------------|--|--|
| CA | BG | WO 98/07697 | 02-26-1998 | Pfizer Inc. | | |
| CA | BH | WO 98/14451 | 04-09-1998 | Novartis AG | | |
| CA | BI | WO 98/23613 | 06-04-1998 | Pfizer Inc. | | |
| CA | BJ | WO 98/30566 | 07-16-1998 | Pfizer Inc. | | |
| CA | BK | WO 98/33768 | 08-06-1998 | Pfizer Products Inc. | | |
| CA | BL | WO 98/34918 | 08-13-1998 | Pfizer Inc. | | |
| CA | BM | WO 98/34915 | 08-13-1998 | Pfizer Inc. | | |
| CA | BN | WO 98/50356 | 11-12-1998 | Sugen, Inc. | | |
| CA | BO | WO 98/54093 | 12-03-1998 | Merck & Co., Inc. | | |
| CA | BP | WO 99/00797 | 01-07-1999 | Aplus Flash Technology, Inc. | | |
| CA | BQ | WO 99/10349 | 03-04-1999 | Zeneca Limited | | |
| CA | BR | WO 99/16755 | 04-08-1999 | Merck & Co., Inc. | | |
| CA | BS | WO 99/21845 | 05-06-1999 | Agouron Pharmaceuticals Inc. | | |
| CA | BT | WO 99/24440 | 05-20-1999 | Pfizer Products Inc. | | |
| CA | BU | WO 99/29667 | 06-17-1999 | Pfizer Limited | | |
| CA | BV | WO 99/35146 | 07-15-1999 | Glaxo Group Limited | | |
| CA | BW | WO 99/35132 | 07-15-1999 | Glaxo Group Limited | | |
| CA | BX | WO 99/52910 | 10-21-1999 | Pfizer Products Inc. | | |
| CA | BY | WO 99/52889 | 10-21-1999 | Pfizer Products Inc. | | |
| CA | BZ | WO 99/61422 | 12-02-1999 | Sugen, Inc. | | |

| | |
|---------------|------------------|
| EXAMINER: | DATE CONSIDERED: |
| <i>AULAKH</i> | <i>9-14-04</i> |

EXAMINER: Initial if reference considered, whether or no citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. Applicant's unique citation designation number (optional). 25a. Kinda Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1459, Alexandria, VA 22313-1459.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)
Complete if Known

| | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | | | | | |
|----|---------|---------------|------------|----------------------|--|--|
| CA | CA | WO 00/38665 | 07-06-2000 | G. D. Searle & Co. | | |
| CA | CB | EP- 0 780 386 | 10-02-2002 | Hoffmann-La Roche AG | | |
| CA | CC | EP- 0 931 788 | 11-16-2002 | Pfizer Inc. | | |
| CA | CC 2 | WO 03/000,194 | 01-03-2003 | Pfizer, Inc. | | |
| CA | CC 3 | WO 03/074,529 | 09-12-2003 | Pfizer, Inc. | | |
| CA | CC 4 | WO 01/94353 | 12-13-2001 | Pfizer Products Inc. | | |

NON PATENT LITERATURE DOCUMENTS

| | | | |
|-------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| CA | CD | BAGSHAWE, et. al., "Antibody-Directed Enzyme Therapy: A Review," <i>Drug Development and Research</i> , 1995, 220-230, 34. | |
| CA | CE | BERTOLINI, et. al., "A New Rational Hypothesis for the Pharmacophore of the Active Metabolite of Leflunomide, a Potent Immunosuppressive Drug," <i>Journal of Medicinal Chemistry</i> , 1997, 2011-2016, 40. | |
| CA | CF | BODOR, et. al., "Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site-Specific Chemical Delivery Systems," <i>Advances in Drug Res.</i> , 1984, 224-331, 13. | |
| CA | CG | BUNDGAARD, et. al., <u>Design and Application of Prodrugs, Drug Design and Development</u> , Harwood Academic Press, 1991. | |
| CA | CH | BUNDGAARD, et. al., <u>Design of Prodrugs</u> , Elsevier Press, 1985, New York. | |
| CA | CI | BUTTERY, et. al., "Preparation of 2,3-Disubstituted Indoles from Indole-3-carboxylic Acids and Amides by Deprotonation," <i>Journal of Chem. Soc. Perkin Trans</i> , 1993, 1425-1431. | |
| CA | CJ | PAGANO, Michele ed., <u>Cell Cycle: Materials and Methods</u> , 1995, Berlin, Germany. | |
| CA | CK | FLEISHER, et. al., "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 1996, 115-130, Vol. 19. | |

EXAMINER:

AULAKH

DATE CONSIDERED:

9-14-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application. ¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

| Complete if Known | |
|------------------------|------------------------|
| Application Number | to be assigned |
| Filing Date | March 9, 2004 |
| First Named Inventor | Michael Collins et al. |
| Art Unit | 1625 |
| Examiner Name | Charanjit Aulakh |
| Attorney Docket Number | PC19103B |

| | | | |
|-----------|---------|------------------|---------|
| EXAMINER: | ALSLAKY | DATE CONSIDERED: | 9-14-04 |
|-----------|---------|------------------|---------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional). 25cc Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901-04. 3Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.